亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台，協助業界發掘知識產權貿易商機，並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權，或是製造商需要購買技術以提高操作效能，又或是知識產權配套服務供應商，你將會從本網站發掘到有用的知識產權貿易資訊。

返回搜索結果

Novel Diabetes Treatment

總結: Researchers at Purdue University in collaboration with Oklahoma Medical Research Foundation have developed and assayed a series of lead compounds that act as memapsin 1 inhibitors and increase pancreatic beta cell mass. Treatment with these compounds may also be complimented by other therapeutics that increase insulin production, improve glucose homeostasis, or inhibit hyperglucagonemia.

*Background: Diabetes is a widely prevalent disease that currently affects 25.8 million people in the United States. The predominant form of diabetes is characterized by hyperglycemia resulting from a combination of reduction in pancreatic beta cell activity and mass, which leads to insufficient insulin production. An enzyme called memapsin 1 is known to be part of the biochemical pathway that leads to the problems with pancreatic beta cells and ultimately causes insulin deficiency. Memapsin 1 deactivates a transmembrane protein shown to increase beta cell proliferation and improve glucose stimulated insulin secretion. The transmembrane protein is deactivated when it undergoes ectodomain cleavage in a process triggered by memapsin 1.

*Web Links: Purdue Office of Technology CommercializationPurdueInnovation and EntrepreneurshipArun GhoshGhosh GroupPurdue Chemistry

欲了解更多信息，請點擊這裡